

Indian Journal of CRITICAL CARE MEDICINE

Peer-reviewed, Official Publication of INDIAN SOCIETY OF CRITICAL CARE MEDICINE

Indian Journal of Critical Care Medicine is indexed/listed with Excerpta Medica/EMBASE, CAB Abstracts, Global Health, CINAHL Database, Cumulative Index to Nursing and Allied Health Literature, MANTIS, Health & Wellness Research Center, Health Reference Center Academic, InfoTrac One File, Expanded Academic ASAP, electronic databases of EBSCO, and Indian Science Abstracts.

Indian Journal of Critical Care Medicine is published quarterly (in March, June, September and December).

The information and opinions presented in Indian Journal of Critical Care Medicine reflect the views of the authors and not of the Society or the Editorial Board. Acceptance does not constitute endorsement by ISCCM.

All the rights are reserved.

Apart from any fair dealing for the purposes of research or private study, or criticism or review, no part of the publication can be reproduced, stored, or transmitted, in any form or by any means, without the prior permission.

Indian Journal of Critical Care Medicine and/or its publisher cannot be held responsible for errors or for any consequences arising from the use of the information contained in this journal. The appearance of advertising or product information in the various sections in the journal does not constitute an endorsement or approval by the journal and/or its publisher of the quality or value of the said product or of claims made for it by its manufacturer.

The Journal is printed on acid free paper.

EDITORIAL OFFICE

Dr. Sandhya Talekar

Chief Editor, IJCCM
Shree Medical Foundation, Prayag Hospital, 1247, Deccan Gymkhana, Pune 411004, India.
Tel: 91 20 553 2812 / 553 2490
Fax: 91 20 553 4448
E-mail: editor@ijccm.org

PUBLISHED BY

Medknow Publications

A-108/109, Kanara Business Center Off Link Rd, Ghatkopar (E), Mumbai - 400075, India.
Phone: 91-22-6649 1818 / 1816,
E-mail: publishing@medknow.com

WEBSITES

www.ijccm.org
www.bioline.org.br/ccm
www.journalonweb.com/ijccm

CHIEF EDITOR

Dr. Sandhya Talekar

sandhya_talekar@yahoo.com

EXECUTIVE EDITOR

Dr. Shirish Prayag

shirishprayag@gmail.com

ASSISTANT EDITORS

Dr. R. K. Mani

rkmjs@vsnl.net

Dr. Farhad Kapadia

fnkapadia@gmail.com

Dr. J. V. Divatia

jdivatia@vsnl.com

MEMBERS OF EDITORIAL BOARD

Dr. S. S. Iyer (Pune)

s_ier@vsnl.com

Dr. N. Ramakrishnan (Chennai)

icudoctor@gmail.com

Dr. Atul Kulkarni (Mumbai)

kaivalyaak@yahoo.co.in

Dr. Lalitha Pillai (Pune)

lalithapillai29@rediffmail.com

PEDIATRIC SECTION

Dr. K. Chugh

gangaram@giasd101.vsnl.net.in

Dr. Pravin Khilnani (New Delhi)

praveenk@nde.vsnl.net.in

Dr. Sunit Singhi (Chandigarh)

drsinghi@glide.net.in

Dr. Soonu Udani (Mumbai)

drudani@hotmail.com

NATIONAL ADVISORY BOARD

Dr. M. B. Agarwal

Dr. Dilip Karnad

Dr. Manimala S. Rao

Dr. F. E. Udwadia

Dr. H. S. Ballal

Dr. Ram Rajagopalan

Dr. Subhash Todi

Dr. R. S. Wadia

INTERNATIONAL ADVISORY BOARD

Dr. David Baker (France)

Dr. Geoffrey Dobb (Australia)

Dr. Ken Hillman

Dr. Mitchell Levy (USA)

Dr. Michael Parr (Australia)

Dr. Ian Seppelt (Australia)

Dr. Laurent Brochard (France)

Dr. K. Guntupalli (USA)

Dr. Roop Kishen (UK)

Dr. Ramesh Nagappan (Australia)

Dr. Gilbert Park (UK)

Dr. J. L. Vincent (Belgium)

Indian Journal of CRITICAL CARE MEDICINE

Official publication of Indian Society of Critical Care Medicine

Oct-Dec 2007

Volume 11, Issue 4

C O N T E N T S

Editorials

- It is not just the work - It is also the words**
– Murali Ramaswam _____ 169
- The ideal transfusion trigger in critically ill patients**
– M. B. Agarwal _____ 173

Original Articles

- An increase in weight worsens the respiratory state and leads to intensive care unit re-admission**
– Yoshinori Matsuoka, Akinori Zaitso _____ 176
- A prospective cohort study on anemia and blood transfusion in critically ill patients**
– Naveen Manchal, S. Jayaram _____ 182
- Comparison of norepinephrine and dopamine in the management of septic shock using impedance cardiography**
– Sharad K. Mathur, Rajiv Dhunna, Arpan Chakraborty _____ 186
- Determination of intravascular volume status in critically ill patients using portable chest X-rays: Measurement of the vascular pedicle width**
– Nawal Salahuddin, M. Aslam, Ishtiaq Chishti, Shehla Siddiqui _____ 192
- Role of physiotherapists in intensive care units of India: A multicenter survey**
– Jithendra A. Kumar, Arun G. Maiya, Daphne Pereira _____ 198

Review Article

- Postoperative pain and its management**
– Sona Chaturvedi, Amit Chaturvedi _____ 204

Case Reports

- Rhabdomyolysis due to hair dye poisoning: An emerging threat**
– Krishnaswamy Sampathkumar, Yesudas Santhakumari Sooraj, Rajappannair Prabha Ajeshkumar, Amol Ramesh Mahaldar, Ramakrishnan Muthiah _____ 212
- Severe hyperkalemia with normal electrocardiogram**
– Sanjay Sharma, Harish Gupta, Meena Ghosh, Anantanarayan Padmanabhan _____ 215

International Conference Calendar _____ 218

Author Index - 2007 _____ 000??

Title Index - 2007 _____ 000??

Comparison of norepinephrine and dopamine in the management of septic shock using impedance cardiography

Sharad K. Mathur, Rajiv Dhunna*, Arpan Chakraborty**

Abstract

Objective: Vasoconstrictors are one of the therapeutic modalities in the treatment of septic shock. In the present study, we have compared the effects of dopamine and norepinephrine in the treatment of septic shock with pre-defined end-points and continuous non-invasive cardiac output monitoring using impedance cardiography.

Design: Randomized controlled trial. **Settings:** Sixteen-bedded mixed intensive care unit of a tertiary care teaching institution. **Materials and Methods:** The study included 50 consecutive patients presenting with septic shock and divided randomly into two groups with 25 patients in each group. Group I patients were treated with dopamine and those in Group II were treated with norepinephrine. They were optimized with fluid resuscitation upto CVP > 10 cm of H₂O, packed red cells transfusion upto hematocrit > 30, oxygenation and ventilation upto PaO₂ > 60 mmHg before the inotropes were started. The goal of therapy was to achieve and maintain for six hours, all of the following: (1) SBP > 90 mm Hg, (2) SVRI > 1100 dynes.s/cm⁵m², (3) Cardiac Index > 4.0 L/min/m², (4) IDO₂ > 550 ml/min/m² and (5) IVO₂ > 150 ml/min/m². **Measurements:** The demographic data, baseline parameters and post-treatment parameters were statistically analyzed by using t-test. **Results:** The post-treatment parameters were statistically significant showing the superiority of norepinephrine over dopamine in optimization of hemodynamics and patient survival. Significant improvement in systolic blood pressure, heart rate, cardiac index, SVRI, IVO₂ and urine output were found in norepinephrine group than the dopamine group. Dopamine showed a response in 10 out of 25 patients up to a maximum dose of 25 mcg/kg/min while with norepinephrine, 19 patients responded up to a maximum dose of 2.5 mcg/kg/min. The hemodynamic parameters were preserved in norepinephrine group with better preservation of organ perfusion and oxygen utilization with maintenance of splanchnic and renal blood flow as evidenced by significant increase in O₂ uptake and urine flow. **Conclusion:** Norepinephrine was more useful in reversing the hemodynamic and metabolic abnormalities of septic shock compared to dopamine at the doses tested.

Key words: Dopamine, impedance cardiography, norepinephrine

From:

Department of Anesthesiology, Institute of Medical Sciences, Banaras Hindu University, Varanasi - 221 005, *Medical Intensive Care Unit, Fortis Hospital, Chandigarh; **Rabindranath Tagore International Institute of Cardiac Sciences, Kolkatta, India

Correspondence:

Arpan Chakraborty, Department of Anesthesiology, Rabindranath Tagore International Institute of Cardiac Sciences, Kolkatta, India.
E-mail: arpan_1977@sify.com

Introduction

Sepsis, inflammatory response to infection, directly or indirectly contributes to mortality in majority of the critically ill patients. An elevated cardiac index and a decreased systemic vascular resistance leading to hypotension and hypoperfusion of vital organs characterize the early stage of septic shock. The hypotensive state is

often not amenable to fluid resuscitation alone and requires institution of vasoactive agents to counter the profound fall in systemic vascular resistance, which is an integral feature of septic shock. Vasoconstrictors are the main stay of treatment in reversing reversing the hemodynamic and metabolic abnormalities of hyperdynamic septic shock.

The more recent trend however focuses on monitoring the variables that have a direct influence on the outcome of septic shock. These include:

1. Systolic and mean arterial pressure (SBP and MAP)
2. Systemic vascular resistance index (SVRI)
3. Cardiac index (CI)
4. Index of delivery of oxygen (IDO_2)
5. Index of oxygen uptake (IVO_2)

These variables may be monitored either invasively or non-invasively. Impedance cardiography, the non-invasive method of cardiac output monitoring, has been found to be a satisfactory substitute for invasive monitoring as it provides essentially similar information and is easier, quicker, cheaper and much safer to use.^[1-6]

Hence in the present study, the efficiency and dose requirement of two vasoconstrictors, dopamine and norepinephrine, were compared with predefined end points and continuous noninvasive hemodynamic monitoring.

Materials and Methods

The study was done in the intensive care unit of Institute of Medical Sciences, Banaras Hindu University, Varanasi and included 50 consecutive patients presenting with septic shock. The study was approved by the ethics committee. An informed consent was taken from the patients or their close relatives to get enrolled. Patients with two or more of the following criteria along with systolic blood pressure less than 90 mm Hg were included - (1) body temperature greater than 38°C or less than 36°C, (2) heart rate greater than 90/min, (3) respiratory rate

greater than 20/min and (4) WBC count more than 12000/cmm or less than 4000/cmm or more than 10% bands. Internal jugular vein and radial artery of the patient was cannulated. The non-invasive cardiac output monitor, IQ System (Wantagh, Inc.) was connected to the patient by ECG lead system.

Crystalloids were used for resuscitation while at the same time packed red blood cells were administered to maintain a hematocrit more than 30. The end point of resuscitation was defined as:

1. CVP more than 10 cm H_2O
2. No further increase or a decrease in cardiac index with any further increase in fluid volume or appearance of clinical features of fluid overload.

The ventilatory status was assessed and was managed simultaneously with either invasive or non-invasive modes of ventilation, so as to maintain PaO_2 more than 60 mmHg and PaCO_2 in a range of 35-40 mmHg. The arterial blood gases were measured at an interval of 30 min until ventilation and oxygenation status was optimized.

Patients enrolled in the study were randomly allocated to two groups according to vasoactive agent used [Table 1]. The outcome assessors were blinded to the drug the patient was receiving. However on their assessment and as per the set protocol of the study, the operator of the syringe pump was asked to change the doses of the drug. The person who manipulated the syringe pump knew what drug the patient was receiving and what were the set aliquots for that drug.

The goal of therapy was to achieve and maintain for six hours, all of the following:

1. SBP more than 90 mm Hg
2. SVRI more than 1100 dynes.s/cm⁵m²
3. Cardiac Index more than 4.0L/min/m²
4. IDO_2 more than 550 ml/min/m²
5. IVO_2 more than 150 ml/min/m²

All the parameters were recorded every 15 min. The

Table 1: Study design

	Group-I (25 patients)	Group-II (25 patients)
Drug used	Dopamine	Norepinephrine
Dose range	10-25 mcg/kg/min	0.5-2.5 mcg/kg/min
Increments	2.5 mcg/kg/min	0.25 mcg/kg/min
Time interval	15 min	15 min
Termination of study	Goal achieved or failure	Goal achieved or failure

“responder” to the vasoactive agent used was a patient who achieved and maintained all the predefined goals of therapy for a period of six hours, in the specified dose range.

Results

The observations from the study were recorded and analyzed. Age, sex, weight and APACHE II scoring at the time of admission in ICU were compared by using student's t-test and the differences in the two groups were found non-significant [Table 2]. The baseline parameters were also found to be insignificant between the two groups [Table 3].

On comparison of the post-treatment parameters (at six hours in responders, or at maximum dose of vasoactive agent in non-responders) all, except IVO₂, were found statistically significant ($P < 0.05$) by using t-test (-4). Systemic vascular resistance index (SVRI) in group I patients increased from a mean of 672.88 ± 32.16 dynes.s/cm⁵m² with only 10 of the 25 patients achieving and maintaining the preset goal of SVRI $> 1,100$ dynes.s/cm⁵m². Group II patients showed a rise in SVRI from a mean baseline of 686.48 ± 31.73 dynes.s/cm⁵m² to a mean post treatment value of 1123.60 ± 185.72 dynes.s/cm⁵m².

Table 2: Demographic data

Parameter	Dopamine group (Mean±SD)	Norepinephrine group (Mean±SD)	P-value
Age (years)	54.60±10.92	52.76±10.41	>0.05
Sex (M: F)	17:8	15:10	>0.05
Weight (kg)	58.32±9.43	56.20±9.11	>0.05
APACHE II	24.56±2.90	25.60±2.31	>0.05

Table 3: Comparison of baseline parameters between dopamine and norepinephrine group

Parameter	Dopamine group (Mean±SD)	Norepinephrine group (Mean±SD)	P-value
Heart rate (/min)	129.32±8.30	132.12±7.30	>0.05
SBP (mmHg)	76.96±7.14	74.31±6.12	>0.05
SVRI (dynes.s/cm ⁵ m ²)	672.88±32.16	686.48±31.73	>0.05
CI (L/min/m ²)	5.28±0.53	5.45±0.57	>0.05
IDO ₂ (ml/min/m ²)	731.71±74.53	756.46±79.04	>0.05
IVO ₂ (ml/min/m ²)	172.74±18.71	179.54±19.23	>0.05
Urine output (ml/kg/hr)	0.37±0.11	0.34±0.28	>0.05

Table 4: Post-treatment response

Group	Responders	Non-responders	Effective dose range in responders (mcg/kg/min)	Survivors
Dopamine group	10	15	15-20	6
Norepinephrine group	19	6	1.5-2.5	11

Cardiac Index (CI) in group I patients demonstrated a significant upswing (5.95 ± 0.22 L/min/m²) from the mean baseline (5.23 ± 0.53 L/min/m²). Group II patients showed no significant rise in CI from the baseline values.

The IDO₂ in group I patients increased from a baseline mean of 731.71 ± 74.54 ml/min/m² to a post treatment mean value of 827.35 ± 31.65 ml/min/m². The mean IDO₂ baseline value in group II patients showed no significant difference from the baseline mean in group I patients. The number of responders, effective dose of the vasopressor used and survivors are tabulated in Table 4.

Discussion

The early stage of septic shock is characterized by an elevated cardiac index and a decreased systemic vascular resistance, leading to hypotension and hypo perfusion of vital organs. One half of non-survivors of sepsis are estimated to die of refractory hypotension.^[7] Therefore, hemodynamic management of the septic patient to support blood pressure and thereby maintain perfusion to vital organs is an important aspect of care.

Hypotension is often not amenable to fluid (crystalloids or colloids) resuscitation alone and requires institution of vasoactive agents to counter the profound fall in systemic vascular resistance, which is an integral feature of septic shock. The controversy still rages regarding the ideal vasoactive agent and no universal agreement exists as to which of the agents available, should be used first.

Dopamine has been used widely as a first choice vasoactive agent in septic shock (Third European Consensus Conference in Intensive Care Medicine - Crit Care Med 1996). However, several studies have failed to demonstrate the restoration of adequate tissue perfusion, even with high doses of dopamine. These studies at the same time proved norepinephrine to be beneficial in restoring and maintaining arterial blood pressure and urine output in septic shock.^[8-10] Concerns regarding excessive vasoconstriction and impairment of tissue perfusion have persisted when using norepinephrine. Studies have shown that parameters of oxygen delivery and consumption are better markers

of effective resuscitation.^[11,12] Our study therefore used parameters such as IDO_2 and IVO_2 , in addition to SBP and SVRI, to assess the comparative efficacy of dopamine and norepinephrine and also to allay concerns regarding their deleterious effects.

Before starting therapy the baseline heart rate of patients of both the groups was high. On treatment with dopamine in group I, heart rate rose significantly above the baseline. On the other hand those patients who were treated with norepinephrine (group II) showed a statistically significant decline in the heart rate compared to baseline. The post treatment increase in heart rate in group I patients was attributed to the chronotropic actions of dopamine, which in some patients led to significant tachyarrhythmia ($\text{HR} > 140/\text{min}$). Tachycardia is primarily due to the β -adrenergic properties of dopamine that predominate in patients with sepsis.^[13] Moreover, the chronotropic sensitivity to β -adrenergic stimulation is increased in sepsis.^[14] This chronotropic effect of dopamine elevates myocardial oxygen demand, which may not be adequately met even by increased coronary blood flow.^[15] Patients on norepinephrine infusion on the other hand demonstrated a favorable profile, leading to a decrease in heart rate compared to the baseline. It can be attributed to an increase in systemic vascular resistance and thereby the MAP, leading to better organ perfusion and oxygen utilization.

Mean baseline SBP in group I patients showed no significant difference with the mean SBP in group II patients. However, post treatment the mean SBP in group II patients rose significantly [Table 5] while patients in group I showed a moderate rise. Only 10 of the 25 patients in group I showed a sustained rise of SBP ($> 90 \text{ mmHg}$ for more than six hours) as opposed to 19 patients in group II. Thus, remaining 15 patients showed a relative dopamine resistance depicted by their inability to achieve and/or

to maintain the preset SVRI and SBP, thereby leading to continued hypoperfusion of organs. Group II patients showed a significant rise in SVRI from the mean baseline value. This difference in the two groups can be attributed to more vasoconstrictive action of norepinephrine as compared to dopamine.

The positive inotropic and chronotropic effects of dopamine are responsible for rise in CI. However, mere rise in CI is not sufficient per se, since studies have shown that survivors as well as non-survivors of septic shock may have a high CI, even within a few hours of death.^[16] Norepinephrine group showed no significant rise in CI from the baseline mean despite the rise in SVRI and SBP. This compared favorably to prior studies, which have shown that a rise in SBP by a potent vasopressor at the expense of cardiac index leads to poor survival.^[17] Moreover the post-treatment IDO_2 in group II patients ($769.63 \pm 80.43 \text{ ml/min/m}^2$) showed no significant rise from its baseline. This showed that the rise in SVRI in group I patients had no deleterious effect on IDO_2 .

Index of uptake of oxygen (IVO_2) in group I increased significantly ($210.62 \pm 11.23 \text{ ml/min/m}^2$) over the mean baseline ($172.74 \pm 18.71 \text{ ml/min/m}^2$). This was primarily attributed to increase in index of delivery of oxygen (IDO_2) and cardiac index (CI) rather than a fall in the venous oxygen content.

Norepinephrine administration demonstrated a significant rise in IVO_2 over the baseline values but it was not statistically significant ($P > 0.05$) when compared to post-treatment IVO_2 in dopamine group. Thus group II patients showed an increase in oxygen uptake by the tissues, which were dependent neither on increased IDO_2 nor CI. This increase in uptake of oxygen in group II patients may be attributed to the correction of splanchnic ischemia. Prior studies have also demonstrated increase in splanchnic blood flow with norepinephrine infusion in sepsis.^[18] Under the influence of norepinephrine vascular reactivity is restored in sepsis towards the areas of greatest oxygen demand, thereby increasing uptake and optimizing oxygen extraction.

Group I patients showed an increase in urine output, while group II patients showed a significantly higher increase as compared to group I. Norepinephrine by virtue of its greater effect on the efferent rather than afferent

Table 5: Comparison of post-treatment parameters between Group I and II

Parameter	Dopamine group (Mean \pm SD)	Norepinephrine group (Mean \pm SD)	P-value
Heart rate (/min)	141.64 \pm 8.67	129.08 \pm 5.86	<0.001
SBP (mmHg)	100.04 \pm 23.36	112.84 \pm 21.21	<0.05
SVRI (dynes.s/cm ⁵ m ²)	922.60 \pm 264.78	1123 \pm 185.72	<0.05
CI (L/min/m ²)	5.95 \pm 0.22	5.53 \pm 0.58	<0.05
IDO_2 (ml/min/m ²)	827.35 \pm 31.65	769.63 \pm 80.43	<0.05
IVO_2 (ml/min/m ²)	210.62 \pm 11.31	202.54 \pm 23.03	>0.05
Urine output (ml/kg/hr)	0.81 \pm 0.75	1.17 \pm 0.47	<0.05

arterioles increases the filtration fraction and helps to increase urine flow, with normalization of renal vascular resistance and also by the decrease in the ADH release.

Group I showed a response in 10 out of 25 patients. The non-responders in this group either failed to achieve and / or to maintain the predefined goals even with the maximum dopamine infusion dose (25 mcg/kg/min). In group II 19 patients responded to norepinephrine infusion upto a dose of 2.5 mcg/kg/min. Thus norepinephrine was more useful in reversing the hemodynamic and metabolic abnormalities of septic shock compared to dopamine at the doses tested. The effective dose range in group I was 15 to 20 mcg/kg/min with no patient responding below or above it whereas in group II the effective dose of norepinephrine was between 1.5 mcg/kg/min to 2.5 mcg/kg/min.

Six patients (24%) in the dopamine group and 11 (44%) patients in the norepinephrine group ultimately survived and were all 'responders'. The predominant cause of mortality in rest of the patients in both groups was multiple organ dysfunction.

The limitation of the study was that it only targeted the achievement of hemodynamic goals for a specific duration and thus the requirement of other vasoactive agents were not mentioned in both responders and non-responders. The inclusion criteria also did not consider the period of shock before starting therapy and the pre-existing organ dysfunction with which they presented to us. Also the requirement of other supportive measures like renal replacement therapy, duration of mechanical ventilation etc. were not taken into account in responders of both group.

Conclusion

The study shows that at the doses tested, norepinephrine is more effective and reliable than dopamine in reversing the hemodynamic and metabolic abnormalities of septic shock and patient survival. It leads to better supply and uptake of oxygen by the tissues. Moreover, norepinephrine shows no adverse effect on peripheral blood flow or on renal blood flow, as evidenced by normalization of urine output.

References

1. Shoemaker WC, Wo CC, Lu K, Chien LC, Rhee P, Bayard D, *et al.* Noninvasive hemodynamic monitoring for combat casualties. *Mil Med* 2006;171:813-20.
2. Shoemaker WC, Wo CC, Yu S, Farjam F, Thangathurai D. Invasive and noninvasive haemodynamic monitoring of acutely ill sepsis and septic shock patients in the emergency department. *Eur J Emerg Med* 2000;7:169-75.
3. Shoemaker WC, Wo CC, Chan L, Ramicone E, Kamel ES, Velmahos GC, Belzberg H. Outcome prediction of emergency patients by noninvasive hemodynamic monitoring. *Chest* 2001;120:528-37.
4. Shoemaker WC, Bayard DS, Botnen A, Wo CC, Gandhi A, Chien LC, *et al.* Mathematical program for outcome prediction and therapeutic support for trauma beginning within 1 hr of admission: A preliminary report. *Crit Care Med.* 2005;33:1647-8.
5. Shoemaker WC, Bishop MH. Noninvasive estimation of CO and circulatory dynamics in critically ill patients. *Curr Opin Crit Care* 1995;1:211-8.
6. Shoemaker WC, Wo CC, Bishop MH. Multi centered trial of a new thoracic electric bioimpedence devise for CO estimation. *Crit Care Med* 1994;22:190-7.
7. Marik PE. Gastric Intramucosal pH a better predictor of multiorgan dysfunction syndrome and death than oxygen-derived variables in patients with sepsis. *Chest* 1993;104:225-9.
8. Martin C, Viviani X, Leone M, Thirion X. Effect of norepinephrine on the outcome of septic shock. *Crit Care Med* 2000;28:2758-65.
9. Mills LC, Moyer JF, Handley CA. Effects of various sympathicomimetic drugs on renal hemodynamics in normotensive and hypotensive dogs. *Am J Physiol* 1960;198:1279-83.
10. Schaer GL, Fink MP, Parillo JE. Norepinephrine alone versus norepinephrine plus low dose dopamine: Enhanced renal blood flow with combination pressure therapy. *Crit Care Med* 1985;13:492-6.
11. Durham RM, Neunaber K, Mazuski JE, Shapiro MJ, Baue AE. The use of oxygen consumption and delivery as endpoints for resuscitation in critically ill patients. *J Trauma* 1996;41:32-40.
12. Shoemaker WC, Appel PL, Kram HB. Oxygen transport measurements to evaluate tissue perfusion and titrate therapy. *Crit Care Med* 1991;19:672-88.
13. Rudis MI, Basha MA, Zarowitz BJ. Is it time to reposition vasopressors and inotropes in sepsis? *Crit Care Med* 1996;24:525-37.
14. Smith LW, Winbery SL, Barker LA, McDonough KH. Cardiac function and chronotropic sensitivity to beta adrenergic stimulation in sepsis. *Am J Physiol* 1986;251:H405-12.

15. Schreuder WO, Schneider AJ, Groenveld AB, Thijs LG. Effect of dopamine vs norepinephrine on hemodynamics in septic shock: Emphasis on right ventricular performance. *Chest* 1989;95:1282-8.
16. Abraham E, Bland RD, Cobo JC, Shoemaker WC. Sequential cardiorespiratory patterns associated with outcome in septic shock. *Chest* 1984;85:75-80.
17. Brown RS, Carrey JS, Mohr PA, Monson DO, Shoemaker WC. Comparative evaluation of sympathomimetic amines in clinical shock. *Circulation* 1966;34:260-71.
18. Takala J, Ruokonen E. Blood flow and adrenergic drugs in septic shock. *In*: Vincent JL, editor. *Update in intensive care and emergency medicine*. Berlin: Springer –Verlag; 1991. p. 144-62.

Source of Support: Nil, **Conflict of Interest:** None declared.